Significance of molecular diagnostics for therapeutic decision-making in recurrent glioma
© The Author(s) 2023. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology..
Background: Targeted therapies have substantially improved survival in cancer patients with malignancies outside the brain. Whether in-depth analysis for molecular alterations may also offer therapeutic avenues in primary brain tumors remains unclear. We herein present our institutional experience for glioma patients discussed in our interdisciplinary molecular tumor board (MTB) implemented at the Comprehensive Cancer Center Munich (LMU).
Methods: We retrospectively searched the database of the MTB for all recurrent glioma patients after previous therapy. Recommendations were based on next-generation sequencing results of individual patient's tumor tissue. Clinical and molecular information, previous therapy regimens, and outcome parameters were collected.
Results: Overall, 73 consecutive recurrent glioma patients were identified. In the median, advanced molecular testing was initiated with the third tumor recurrence. The median turnaround time between initiation of molecular profiling and MTB case discussion was 48 ± 75 days (range: 32-536 days). Targetable mutations were found for 50 recurrent glioma patients (68.5%). IDH1 mutation (27/73; 37%), epidermal growth factor receptor amplification (19/73; 26%), and NF1 mutation (8/73; 11%) were the most detected alterations and a molecular-based treatment recommendation could be made for all of them. Therapeutic recommendations were implemented in 12 cases (24%) and one-third of these heavily pretreated patients experienced clinical benefit with at least disease stabilization.
Conclusions: In-depth molecular analysis of tumor tissue may guide targeted therapy also in brain tumor patients and considerable antitumor effects might be observed in selected cases. However, future studies to corroborate our results are needed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
Neuro-oncology advances - 5(2023), 1 vom: 28. Jan., Seite vdad060 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Blobner, Jens [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Revised 10.06.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/noajnl/vdad060 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357895436 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357895436 | ||
| 003 | DE-627 | ||
| 005 | 20231226073557.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/noajnl/vdad060 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1192.xml |
| 035 | |a (DE-627)NLM357895436 | ||
| 035 | |a (NLM)37287694 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Blobner, Jens |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Significance of molecular diagnostics for therapeutic decision-making in recurrent glioma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.06.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. | ||
| 520 | |a Background: Targeted therapies have substantially improved survival in cancer patients with malignancies outside the brain. Whether in-depth analysis for molecular alterations may also offer therapeutic avenues in primary brain tumors remains unclear. We herein present our institutional experience for glioma patients discussed in our interdisciplinary molecular tumor board (MTB) implemented at the Comprehensive Cancer Center Munich (LMU) | ||
| 520 | |a Methods: We retrospectively searched the database of the MTB for all recurrent glioma patients after previous therapy. Recommendations were based on next-generation sequencing results of individual patient's tumor tissue. Clinical and molecular information, previous therapy regimens, and outcome parameters were collected | ||
| 520 | |a Results: Overall, 73 consecutive recurrent glioma patients were identified. In the median, advanced molecular testing was initiated with the third tumor recurrence. The median turnaround time between initiation of molecular profiling and MTB case discussion was 48 ± 75 days (range: 32-536 days). Targetable mutations were found for 50 recurrent glioma patients (68.5%). IDH1 mutation (27/73; 37%), epidermal growth factor receptor amplification (19/73; 26%), and NF1 mutation (8/73; 11%) were the most detected alterations and a molecular-based treatment recommendation could be made for all of them. Therapeutic recommendations were implemented in 12 cases (24%) and one-third of these heavily pretreated patients experienced clinical benefit with at least disease stabilization | ||
| 520 | |a Conclusions: In-depth molecular analysis of tumor tissue may guide targeted therapy also in brain tumor patients and considerable antitumor effects might be observed in selected cases. However, future studies to corroborate our results are needed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a molecular tumor board | |
| 650 | 4 | |a molecular-matched targeted therapy | |
| 650 | 4 | |a recurrent glioma | |
| 700 | 1 | |a Dengler, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Blobner, Sven |e verfasserin |4 aut | |
| 700 | 1 | |a Eberle, Constantin |e verfasserin |4 aut | |
| 700 | 1 | |a Weller, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Teske, Nico |e verfasserin |4 aut | |
| 700 | 1 | |a Karschnia, Philipp |e verfasserin |4 aut | |
| 700 | 1 | |a Rühlmann, Katharina |e verfasserin |4 aut | |
| 700 | 1 | |a Heinrich, Kathrin |e verfasserin |4 aut | |
| 700 | 1 | |a Ziemann, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Greif, Philipp A |e verfasserin |4 aut | |
| 700 | 1 | |a Jeremias, Irmela |e verfasserin |4 aut | |
| 700 | 1 | |a Wuerstlein, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Hasselmann, Korbinian |e verfasserin |4 aut | |
| 700 | 1 | |a Dorostkar, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Harter, Patrick N |e verfasserin |4 aut | |
| 700 | 1 | |a Quach, Stefanie |e verfasserin |4 aut | |
| 700 | 1 | |a Stoecklein, Veit |e verfasserin |4 aut | |
| 700 | 1 | |a Albert, Nathalie L |e verfasserin |4 aut | |
| 700 | 1 | |a Niyazi, Maximilian |e verfasserin |4 aut | |
| 700 | 1 | |a Tonn, Joerg-Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Thon, Niklas |e verfasserin |4 aut | |
| 700 | 1 | |a Christoph Westphalen, Benedikt |e verfasserin |4 aut | |
| 700 | 1 | |a von Baumgarten, Louisa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuro-oncology advances |d 2019 |g 5(2023), 1 vom: 28. Jan., Seite vdad060 |w (DE-627)NLM302151087 |x 2632-2498 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2023 |g number:1 |g day:28 |g month:01 |g pages:vdad060 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/noajnl/vdad060 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2023 |e 1 |b 28 |c 01 |h vdad060 | ||